Kodiak Sciences Inc
KODNext catalyst
Phase 3 — KSI-101
Get an email about KOD's next catalysts
Track Kodiak Sciences (KOD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (earnings, Phase 3 readout).See the timeline
4 upcoming, 0 past
KOD Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $1.00 | FQ end Sep/2026 | Call: tbd
Phase 3 — KSI-101
For Macular edema secondary to inflammation. Kodiak Sciences completed enrollment in the first pivotal cohort of the Phase 3 PEAK trial evaluating KSI-101 for macular edema secondary to inflammation, with topline clinical data expected in December 2026.
SourceKSI-101 Phase 3 Est. Readout (PINNACLE)
Estimated primary completion for KSI-101 trial (NCT06996080) in Macular Edema Secondary to Inflammation. Topline data typically follows completion by weeks to months.
SourceKSI-101 Phase 3 Est. Readout (PEAK)
Estimated primary completion for KSI-101 trial (NCT06990399) in Macular Edema Secondary to Inflammation. Topline data typically follows completion by weeks to months.
SourceHow KOD's past catalysts played out
Market Overview
Stock performance and key metrics
KSI-101
Macular Edema Secondary to Inflammation
KSI-301
Macular Edema
Tarcocimab
Diabetic Retinopathy
Tarcocimab tedromer
Wet Age-related Macular Degeneration
Tabirafusp tedromer
Diabetic Macular Edema (DME)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KSI-101 | Phase 3 | Macular Edema Secondary to Inflammation | - | - |
KSI-301 | Phase 3 | Macular Edema | - | - |
Tarcocimab | Phase 3 | Diabetic Retinopathy | - | - |
Tarcocimab tedromer | Phase 3 | Wet Age-related Macular Degeneration | - | - |
Tabirafusp tedromer | Phase 3 | Diabetic Macular Edema (DME) | - | - |
Wet Age-related Macular Degeneration
2 drugs in this indication
Macular Edema Secondary to Inflammation
1 drug in this indication
Diabetic Retinopathy
1 drug in this indication
Macular Edema
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Kodiak Sciences Inc's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Kodiak Sciences Inc's (KOD) pipeline across Phase 3. Its lead program is KSI-101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kodiak Sciences Inc's next FDA catalyst?→
Kodiak Sciences Inc's (KOD) next tracked catalyst is a Phase 3 readout expected Dec 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KOD biotech catalysts?→
Add KOD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kodiak Sciences Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.